



# Collaborating with Pfizer: Advancing Innovative Emerging Science

April 12, 2021 | 3:10 - 3:55 PM ET



**Moderator:**  
**Jennifer Lodge**  
Washington University,  
St. Louis



**Gerald Shipps**  
Pfizer



**Joel Klappenbach**  
Pfizer



Strengthening  
University-Industry  
Partnerships


## TECH SUPPORT

### Having technical problems?

Look for the Tech Q&A doc in chat on the right side of your screen.

Or email [info@uidp.net](mailto:info@uidp.net).

If the session shuts down due to connection issues, do NOT close the Attendee Hub window. The room will reopen just a couple of minutes.




Strengthening  
University-Industry  
Partnerships

# how to PARTICIPATE

## Live Chat and Q&A

At the right of your screen

- Chat with one another
- Submit questions using the Q&A




# how to PARTICIPATE

---

## Handouts and Recordings

- Download available handouts from the Session Content tab on the bottom of your screen.
- Session recordings will be posted in the Attendee Hub. You will be notified via email when they are available at uidp.org.



# Collaborating with Pfizer

*Advancing the Most Innovative External Science*

UIDP Discussion  
April 12, 2021



---

# FORWARD LOOKING STATEMENTS

This presentation includes forward-looking statements about, among other things, our research and development program, expectations for our product pipeline, in-line products and product candidates, including anticipated regulatory submissions, data read-outs, study starts, approvals, post-approval clinical trial results and other developing data that become available, revenue contribution, growth, performance, timing of exclusivity and potential benefit and other statements about our business, operations and financial results that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These statements are subject to risks, uncertainties and other factors that may cause actual results to differ materially from past results, future plans and projected future results. Additional information regarding these and other factors can be found in Pfizer's Annual Report on Form 10-K for the fiscal year ended December 31, 2020 and in our subsequent reports on Form 10-Q, including in the sections thereof captioned "Risk Factors" and "Forward-Looking Information and Factors That May Affect Future Results", as well as in our subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission (the "SEC") and available at [www.sec.gov](http://www.sec.gov) and [www.pfizer.com](http://www.pfizer.com). The forward-looking statements in this presentation speak only as of the original date of this presentation and we undertake no obligation to update or revise any of these statements.

# Many Ways to Work with Pfizer

*We build academic, global public-private and biotech partnerships to help deliver first-in-class science and potentially bring medicines to the world faster. There are many ways to collaborate with Pfizer including but not limited to:*



**JOINT DRUG  
DISCOVERY**



**LICENSING**



**SEED & VENTURE  
INVESTMENTS**



**RESEARCH  
COLLABORATIONS**



**OPTIONS-BASED  
DEALS**



**ACQUISITIONS**  
*(of asset or company)*

# Focusing on Potential Breakthrough Science in Areas of High Impact

## RARE DISEASES



## ONCOLOGY



## INFLAMMATION & IMMUNOLOGY



## INTERNAL MEDICINE



## VACCINES



### ▼ WRDM'S CORE RESEARCH AREAS ▼

Hematology

Neuro-musc.

Gene Therapy

Tumor Biology

Cancer Immunology

Cancer Vaccines

Rheumatology

NASH

Gastroenterology

Medical Dermatology

Met CV Risk Factors

NASH

High Impact Infections

Maternal

### ▼ EMERGING SCIENCE AREAS ▼

#### Repeat Expansion Diseases



#### DNA Damage Response and Replicative Stress



#### Cellular Senescence





# CTI: Unique Collaborations for Optimal Outcomes

*Collaboration with CTI provides access to Pfizer R&D drug discovery resources, enabling advancement and translation of novel scientific concepts*

Identify the **most promising science** and investigators

*We are dedicated to finding and funding the best external innovation at the earliest stages*

Pair each investigator with a Pfizer **“scientific champion”**

*Our scientists co-lead scientific efforts to manage each project and coordinate access to Pfizer's global capabilities*

**Complementary biology and drug discovery** are performed at Pfizer

*Our joint discovery model combines the investigator subject-matter expertise with Pfizer's infrastructure, scale and networks*

Strive for **optimal outcomes**

*Our collaborations help enable faculty to translate their work into therapeutics with breakthrough potential for patients*


[www.pfizercti.com](http://www.pfizercti.com)

Contact: [contactcti@pfizer.com](mailto:contactcti@pfizer.com)




Emerging Science & Innovation

# Over a Decade of Success at CTI



# A clinical pipeline poised to deliver innovative, potential first-in-class therapies against a wide range of diseases



\*As of January 2021



Emerging Science & Innovation

For more information about Pfizer Clinical Trials go to: [Pfizer.com/clinical-trials](https://www.pfizer.com/clinical-trials)

**The 2021 CTI Call for Proposals** is seeking partnering opportunities for novel targets with applications across Pfizer's core therapeutic areas.

**Submission Deadline: June 28, 2021**

**[www.pfizercti.com](http://www.pfizercti.com) | [contactcti@pfizer.com](mailto:contactcti@pfizer.com)**





Please submit your questions using the questions tab.

Session Chat



Chat



Q&A

- M** Monique Brown  
What's the benefit of changing the check-in process?
- M** Megan Lau  
I think the contactless check-in will be a great way to make our attendees feel more comfortable during in-person events 😊  
👍 3
- D** Doug Brashear  
I can't wait to use these new features for my next event!
- K** Katrina Tanner  
I've noticed the same trends as an event attendee. It's wonderful to learn how event planners are staying current.  
❤️ 7
- C** Chris McAndrews  
Same!
- T** Trevor Lynn  
Does anyone want to connect after the session to discuss what we learned?  
👍 1
- C** Casey Hartnett  
I'm interested



# Training Programs for New Contract Negotiators

April 12, 2021 | 4:15 - 5:30 PM ET



**Moderator:**  
**Elizabeth Adams**  
Princeton



**Sophia Herbert-Peterson**  
Georgia Institute of  
Technology



**Dana Rewoldt**  
Iowa State University



Strengthening  
University-Industry  
Partnerships

THANK YOU!



- Did you enjoy the session? Rate it in the Attendee Hub!
- You'll receive a survey via email about UIDPVirtual at the end of the week. Please give us your feedback.